FindMyKOL
Clinical trialNCT02641639TerminatedPhase 2/PHASE3Interventional

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

SponsorMateon TherapeuticsEnrollment70Platinum Resistant Ovarian Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC). Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs. paclitaxel), platinum free interval (\< 3 vs. 3 to 6 months from last platinum therapy to subsequent progression), and line of therapy (2nd vs. 3rd). This is a 2-part study, consisting of a Phase 2, exploratory study (Part 1) followed by a Phase 3, pivotal study (Part 2). Both parts of the study will have similar overall design. Approximately 80 subjects will be randomized into Part 1 and approximately 356 subjects will be randomized into Part 2.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Uz Leuven

    Leuven, Belgium

Germany
  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Essen (aör) Klinik Für Frauenheilkunde Und Geburtshilfe

    Essen, Germany

  • Universitäts-Frauenklinik Dept. Für Frauengesundheit

    Tübingen, Germany

United States
  • University of Alabama at Birmingham Comprehensive Cancer Center

    Birmingham, Alabama, United States

  • Mitchell Cancer Institute - Usa Health System

    Mobile, Alabama, United States

  • Arizona Oncology Associates, Pc - Hal

    Phoenix, Arizona, United States

  • Arizona Oncology Associates, Pc - Hope

    Tucson, Arizona, United States

  • University of Arizona Cancer Center

    Tucson, Arizona, United States

  • Oncology Institute of Hope and Innovation

    Lynwood, California, United States

  • University of California Irvine

    Orange, California, United States

  • California Pacific Medical Center, Research Institute

    San Francisco, California, United States

  • Sansum Clinic

    Santa Barbara, California, United States

  • Rocky Mountain Cancer Centers, Llp

    Lakewood, Colorado, United States

  • Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering

    Hartford, Connecticut, United States

  • Stamford Hospital - Bennett Cancer Center

    Stamford, Connecticut, United States

  • Baptist Health Medical Group Oncology, Llc

    Miami, Florida, United States

  • Sylvester Comprehensive Cancer Center University of Miami

    Miami, Florida, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Augusta University

    Augusta, Georgia, United States

  • Maine Medical Center

    Scarborough, Maine, United States

  • Mercy Medical Center; the Institute for Cancer Care

    Baltimore, Maryland, United States

  • Hca Midwest Division - Sarah Cannon Cancer Institute

    Kansas City, Missouri, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Gabrail Cancer Center

    Canton, Ohio, United States

  • Oklahoma Heath Sciences Center - Stephenson Cancer Center

    Oklahoma City, Oklahoma, United States

  • Tulsa Cancer Institute

    Tulsa, Oklahoma, United States

  • Ohsu Center for Women'S Health & Knight Cancer Institute

    Portland, Oregon, United States

  • Willamette Valley Cancer Institute

    Springfield, Oregon, United States

  • Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering

    Allentown, Pennsylvania, United States

  • the Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania, United States

  • Gibbs Cancer Center & Research Institute Spartanburg Medical Center

    Spartanburg, South Carolina, United States

  • Texas Oncology, P.A.

    Austin, Texas, United States

  • Texas Oncology

    Bedford, Texas, United States

  • Dallas County Hospital District D/b/a Parkland Health and Hospital System

    Dallas, Texas, United States

  • Simmons Comprehensive Cancer Center; Ut Southwestern Medical Center

    Dallas, Texas, United States

  • Texas Oncology, P.A.

    Dallas, Texas, United States

  • Texas Oncology San Antonio

    San Antonio, Texas, United States

  • Texas Oncology, P.A.

    The Woodlands, Texas, United States

  • Texas Oncology, P.A.

    Tyler, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fosbretabulin TromethaminePlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2016
Primary completion
31 Oct 2017
Completion
31 Oct 2017
Last update posted
24 Mar 2025
Registered enrollment
70
Registry id
NCT02641639

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.